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Zusammenfassung
Schwangerschaft als lebensspendende Phase unseres
Daseins und lebensbedrohende Malignome sind schon
aus naheliegenden psychologischen Gründen nur schwer
miteinander in Zusammenhang zu bringen. Symptome,
die auf ein Malignom hindeuten, werden nicht selten von
Patientin und Arzt ignoriert, woraus neben der erschwer-
ten bildgebenden Diagnostik vermutlich die nachweis-
liche Verzögerung im Nachweis von Mammakarzinomen
während der Schwangerschaft resultiert. Die Diagnostik
und Therapie des Mammkarzinoms gewinnt zunehmend
an Bedeutung, da die späte Realisierung des Kinder-
wunschs die Schwangerschaft zunehmend in ein Lebens-
alter mit höherem Karzinomrisiko rückt und höhere
Heilungsraten von soliden Tumoren eine nachfolgende
Schwangerschaft nicht mehr grundsätzlich ausschließen.
Der folgende Artikel fasst die Besonderheiten von Dia-
gnostik und Primärtherapie des schwangerschaftsasso-
ziierten Mammakarzinoms unter besonderer Berücksich-
tigung der zytostatischen Therapie zusammen.
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Summary
For obvious psychological reasons it is difficult to associ-
ate pregnancy – a life-giving period of our existence –
with life-threatening malignancies. Symptoms pointing
to malignancy are often ignored by both patients and
physicians, and this, together with the greater difficulty
of diagnostic imaging, probably results in the proven
delay in the detection of breast cancers during pregnan-
cy. The diagnosis and treatment of breast cancer are be-
coming more and more important, as the fulfillment of
the desire to have children is increasingly postponed
until a later age associated with a higher risk of carcino-
ma, and improved cure rates of solid tumors no longer
exclude subsequent pregnancies. The following article
summarizes the special features of the diagnosis and pri-
mary therapy of pregnancy-associated breast cancer
with particular consideration of cytostatic therapy.
Introduction
For obvious psychological reasons it is difficult to associate
pregnancy – a life-giving period of our existence – with life-
threatening malignancies. Symptoms pointing to malignancy
are often ignored by both patients and physicians, and this, to-
gether with the greater difficulty of diagnostic imaging, proba-
bly results in the proven delay in the detection of breast can-
cers during pregnancy [1–4]. The diagnosis and treatment of
breast cancer are becoming more and more important, as the
fulfillment of the desire to have children is increasingly post-
poned until a later age associated with a higher risk of carci-
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noma, and improved cure rates of solid tumors no longer ex-
clude subsequent pregnancies [5–9]. Various ethical aspects
considering potential conflicts between optimizing maternal
prognosis and prolonging pregnancy will have to become part
of an informed consent between physicians and patients. This
dialogue, however, has to be based on the profound knowl-
edge of the state of the art in the treatment of pregnancy-
associated breast cancer. The following article summarizes the
special features of the diagnosis and primary therapy of preg-
nancy-associated breast cancer with particular consideration
of cytostatic therapy.
Epidemiology and Prognosis
Pregnancy-associated breast cancer is defined as breast can-
cer occurring during pregnancy or up to 1 year postpartum
[10]. The incidence is increasing particularly in women having
children in the last third of the fertile period of their lives.
With an incidence of 1 in 3,000 to 1 in 10,000 pregnancies,
pregnancy-associated breast cancer is the most common solid
tumor during pregnancy after cervical carcinoma [11, 12].
The prognosis of pregnancy-associated breast cancer is iden-
tical with that of similar tumor stages outside of pregnancy,
with an overall survival rate of 57% 5 years after the initial
diagnosis [13]. However, pregnancy-associated breast cancer
is often diagnosed in the more advanced stages of the disease,
which might be due to delayed discovery as well as a more
aggressive tumor biology.
Diagnosis
Making the diagnosis is rendered more difficult by the
changed consistency and increased weight of the breast dur-
ing pregnancy and lactation. Pregnancy delays the diagnosis
of breast cancer by an average of 2–6 months [1–4]. A Norwe-
gian study calculated that the diagnosis was delayed by 2.5
months during pregnancy and 6 months during the lactation
period [4]. In a similar study by the M.D. Anderson Cancer
Center, an average tumor size of pregnancy-associated breast
cancer of 3.5 cm at the time of diagnosis was observed [10].
While mammography during pregnancy can be classified as a
safe procedure with regard to the fetal radiation load of ap-
proximately 0.004 Gy [14], it often leads to false-negative re-
sults due to the altered radiodensity of the breast [2, 3]. Mam-
mography plays a special role in imaging of undefined pal-
pable lesions during pregnancy and lactation, but must be
treated with particular care. For this reason, ultrasound exam-
ination of the breast is the method of choice for clarifying pal-
pable abnormalities. It is capable of distinguishing between
solid and cystic lesions with 97% certainty [2, 3]. In a Japanese
study, ultrasound examination of the breast showed a sensitiv-
ity of 93% (n = 42) [2]. Magnetic resonance imaging is recom-
mended only in exceptional cases because of the transplacen-
tal action of the contrast agent, the potential heating of the
fetus and the increased hypervascularity in pregnancy and lac-
tation which limits the diagnostic value [14]. Screening for
metastases with an increased radiation load (e.g. computed
tomography, isotope bone scan) should be reserved for situa-
tions in which direct therapeutic consequences are derived
from these investigations [15].
The diagnosis should be made primarily by punch biopsy for
reasons that generally apply to breast cancer [16–18]. The risk
of so-called ‘milk fistulas’ is generally low so that weaning is
not obligatory. Due to the hypervascularity during and after
pregnancy, the use of compression dressings to prevent
hematomas is recommended [10]. The pathologist should al-
ways be informed of the patient’s gravid status in order to
avoid incorrect diagnosis due to pregnancy-associated tissue
changes.
Histopathological Features
The great majority of pregnancy-associated breast cancers
(75–90%) are of the invasive ductal type [1, 2, 19]. The tumor
extent is in every respect more advanced than outside of preg-
nancy. Pregnancy-associated breast cancer is connected with
generally bigger tumors and more frequent axillary lymph
node metastases and distant metastases. Also, hemangiosis
carcinomatosa is observed more often at presentation [2,
19–22]. Views differ on whether this phenomenon is a result
of the delayed diagnosis or whether the disease dynamics are
accelerated by pregnancy-associated factors such as altered
vascularity, higher serum hormone levels or pregnancy-associ-
ated immunosuppression. Furthermore, the estrogen receptor
status of pregnancy-associated breast cancer patients is nega-
tive much more often than that of age-matched control
groups, which may be caused by down-regulation of the hor-
mone receptor [1, 2, 13, 22–27]. More recent investigations
have also shown that HER2/neu overexpression is encoun-
tered more often in pregnancy-associated breast cancer (58%
of cases) [26].
Surgery and Radiotherapy
In principle, the locoregional therapy of pregnancy-associated
breast cancer is in accordance with the general guidelines for
breast cancer therapy. Since there are no conclusive data on
primary systemic therapy in pregnant patients, surgery is the
primary treatment in most cases. Exceptions in the pregnant
situation also include inflammatory or locally advanced carci-
nomas where primary surgery is not appropriate. The risk of
abortion due to surgery involving general anesthesia is slight-
ly increased (rate ratio 1.6–2). Breast-preserving surgery
should be attempted and is associated with results similar to
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those obtained with mastectomy [28, 29]. Because of the high
incidence of axillary lymph node metastases (56–83%) [21],
systematic axillary dissection is regarded as the gold standard.
In recently published studies, measurements of activity after
radionuclide labeling in the region of the breast and axilla
yielded undetectable or very low radioactivity in the pelvis so
that it appears unlikely that the fetus is at risk after sentinel
node biopsy. However, because of the absence of clinical data,
sentinel lymph node excision with radiotracer labeling should
only be performed when strictly indicated [30, 31].
Radiation of the breast and/or chest wall is usually not per-
formed during pregnancy because of the risk of malformation
and radiotherapy-associated malignancies of the fetus. The
risk increase of fetal malignancy is 6.57 cases/10,000/rad/y
[32]. Since due to the usually advanced tumor stage, the risk
of systemic recurrence predominates in the majority of pa-
tients, local radiotherapy is in most cases given only after the
conclusion of systemic therapy and hence after the pregnancy.
Lactation may be impaired after radiation of the breast [23].
Cytostatic Therapy
Chemotherapy is indicated in the majority of patients with
pregnancy-associated breast cancer. After the first trimester,
anthracycline-containing chemotherapy is regarded as the
treatment standard just as in non-pregnancy-associated breast
cancer. In the only prospective study to be carried out on the
use of FAC chemotherapy (5-fluorouracil, doxorubicin, cy-
clophosphamide) during pregnancy, no fetal anomalies were
observed [23]. In general, in breast cancer treatment, anthra-
cyclines are regarded as the drugs with the best benefit-risk
relationship, while folate antagonists, such as methotrexate,
are strictly contraindicated, as they are the main cause of fetal
malformation [33]. The systemic use of cytostatic substances
during pregnancy must be indicated particularly strictly, as it
not only poses risks for the mother but also substantial haz-
ards for the fetus. In principle, the benefits of chemotherapy
during pregnancy for the mother must always be weighed
against the resulting risks for the fetus, and this situation must
be taken into account in the selection, dosage, number of
cycles and administration of cytostatic agents [34].
Undoubtedly, the risk for the fetus is highest when chemo-
therapy is given during the first trimester of pregnancy – the
period of gestation in which the dynamics of organogenesis
make the embryonic organism particularly vulnerable to cyto-
static substances. There is a significantly increased risk of
abortion and fetal anomalies, which appears to be greatest
between weeks 2 and 8 post-conception [35–37]. In a study by
the National Cancer Institute (NCI), all but 2 of 52 chemo-
therapy-associated fetal anomalies had occurred following
chemotherapy during the first trimester. As the risk of fetal
malformation is 16% in the first trimester compared to 1.3%
in the later stages of pregnancy [38], cytostatic therapy should
in principle be avoided during this time. After organogenesis
is concluded, the hematopoietic system, the central nervous
system, the eyes and the ears remain more at risk than other
fetal organs [39]. Although the risk of malformation rapidly
decreases in the second and third trimester, the risk of in-
trauterine growth retardation and premature delivery due to
cytostatic treatment is increased [40]. However, observational
studies have not found any learning disorders or hemato-
logical or immunological abnormalities in children up to early
school age [41].
Anthracyclines exert their effect by incorporating the high-
molecular-weight substance into the DNA. Most data during
pregnancy have been obtained with doxorubicin. Fetal mal-
formation occurred in more than 200 patients, but only when
the cytostatic drug was used during the first trimester as op-
posed to later gestational periods [42–47]. As experiences
with the use of epirubicin in pregnancy are much more limited
(n = 13) [48, 49], doxorubicin should be the drug of choice, if
an efficacy similar to that of epirubicin can be assumed, as is
the case with breast cancer. However, the question remains
whether fetal cardiotoxicity is a result of the transplacental
action of the anthracyclines, which is observed dose-depen-
dently in adults. In an echocardiographic study of fetuses be-
tween weeks 20 and 40 of pregnancy, no increase in cardiomy-
opathy was found when anthracycline-unloaded fetuses were
compared to chemotherapy-loaded fetuses [50]. Because of
the lack of long-term experience with this substance group,
however, appropriate caution is required when considering
the indication, as 4 cases of postnatally diagnosed cardiotoxic-
ity have been reported after intrauterine anthracycline load-
ing. Therefore, signs of postnatal heart failure should be par-
ticularly watched out for [51, 52].
Antimetabolites, such as the folate antagonist methotrexate,
represent the most problematic group of cytostatics with re-
gard to their use in pregnancy. They inhibit the cell metabolism
by being incorporated as false substrates during DNA or RNA
synthesis regardless of the cell cycle. Methotrexate in a dose of
more than 10 mg/week causes malformations in the first
trimester similar to those of the aminopterin syndrome: cranial
dysostosis, disorders of bone maturation, hypertelorism, broad
nasal saddle, micrognathia and ear deformities. Following ad-
ministration of the antimetabolite 5-fluorouracil during preg-
nancy, a total of 53 cases were described with different out-
come, ranging from unremarkable courses to intrauterine fetal
death. Intrauterine growth retardation was observed in 11% of
cases [53, 54]. The antimetabolites cytarabine and mercapto-
purine are not used in gynecological oncology.
Alkylating agents, in particular cyclophosphamide, are also an
integral part of common chemotherapy schedules for the
treatment of breast cancer. A range of malformations, such as
limb, eye and ear deformities, have been observed following
the use of cyclophosphamide during the first trimester
[55–57]. From the second trimester, alkylating agents can ap-
parently be used with much lower risks. Of 92 documented
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cases, 2 fetuses died intrauterinely, in each case when the alky-
lating agent was combined with other cytostatics [58]. In-
trauterine growth retardation was observed in 7% of cases
[59]. The alkylating agents dacarbazine and busulfan are not
used in gynecological oncology, and there are no conclusive
results regarding ifosfamide. Chemotherapy regimens which
have been extensively evaluated and have shown acceptable
safety are summarized in table 1.
No or little data is available on newer agents which have
proven increased efficacy in the treatment of breast cancer,
such as paclitaxel, docetaxel, gemcitabine or capecitabine.
Despite the vast experience with taxanes of almost 10 years,
only 2 case reports are currently available on the use of tax-
anes in pregnant patients [60–62]. Considering the modest
overall survival benefit of the novel agents in comparison to
conventional chemotherapy, such as FEC (5-fluorouracil,
epirubicin, cyclophosphamide), the authors recommend fa-
voring cytostatic regimes which have been extensively eva-
luated.
The timing of chemotherapy during pregnancy should in prin-
ciple be aimed at completing the final cycle at least 2–4 weeks
before the (planned) birth, as both the maternal and the fetal
chemotherapy-induced side effects can lead to a significant in-
crease in intra- and postpartum complications. At the time of
birth, myelosuppression in the mother should have passed the
leukocyte nadir in order to minimize the risk of peripartum
infection. Moreover, the organs of the neonate are not
capable of sufficiently metabolizing cytostatics still present in
the fetal body without the transplacental detoxification assis-
tance of the mother [23, 63, 64].
Endocrine Therapy
Adjuvant endocrine therapy with anti-estrogens during preg-
nancy is contraindicated for 2 reasons: on the one hand, a
range of tamoxifen-associated fetal anomalies are found in
the literature [65, 66], and on the other hand, there is current-
ly no evidence that endocrine therapy during pregnancy leads
to an improved prognosis. This observation might be attribut-
able to the fact that most pregnancy-associated breast cancers
are hormone receptor-negative. Analogously, iatrogenic in-
duction of menopause does not lead to an improved progno-
sis. In fact, in 2 studies, a worsening of the prognosis was ob-
served in patients who had undergone oophorectomy [2, 20].
Termination of pregnancy does not lead to an improved prog-
nosis either but may actually impair the prognosis, and it is
not indicated from an oncological point of view [12, 67].
Further Family Planning
Premenopausal breast cancer patients who want to have chil-
dren frequently seek advice on further family planning after
successful conclusion of the primary breast cancer treatment.
Unfortunately, all available recommendations are without ad-
equate evidence [10, 68]. So far, the originally anticipated in-
crease in the risk of recurrence due to the endocrine changes
during pregnancy has not been confirmed by any study [69].
However, the survival advantage postulated in a few studies
of patients who became pregnant in the years following suc-
cessful treatment of breast cancer is presumably based on a
‘healthy mother effect’ [10, 70]. Despite this fact, there is not
data indicating that pregnancy after successful treatment of
primary breast cancer compromises maternal prognosis. Con-
sequently, fertility-preserving aspects should be considered
when treatment is planned in premenopausal women. Go-
nadotropin-releasing hormone analogues are the only avail-
able medical protection against gonadotoxic chemotherapy.
Assisted reproductive technology offers excellent results but
requires a delay in implementing chemotherapy. Despite re-
cent reports of embryo development after the transplantation
of cryopreserved-thawed ovarian tissue, clinical experience is
limited, and the technique remains experimental [71]. In sum-
mary, the decision for or against having children after the con-
clusion of primary breast cancer treatment should be guided
by personal lifestyle choices rather than vague medical hy-
potheses [72].
Regimen Agents Dosage/administration/interval
4x EC epirubicin 90 mg/m2 / i.v. / d1, q3w, 4 cycles
cyclophosphamide 600 mg/m2 / i.v. / d1, q3w, 4 cycles
FEC120 (Levine) 5-fluorouracil 500 mg/m2 / i.v. / d1+8, q4w, 6 cycles
epirubicin 60 mg/m2 / i.v. / d1+8, q4w, 6 cycles
cyclophosphamide 75 mg/m2 / p.o. / d1–14, q4w, 6 cycles
FEC100 (Bonneterre) 5-fluorouracil 500 mg/m2 / i.v. / d1, q3w
epirubicin 100 mg/m2 / i.v. / d1, q3w
cyclophosphamide 500 mg/m2 / i.v. / d1, q3w
q3w: 3-weekly, q4w: 4-weekly, d: day.
Table 1. Valid chemotherapy regimens in
pregnancy-associated breast cancer
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